An Anti-mutant Approach for Antimicrobial Use

  • Karl Drlica
  • J.-Y. Wang
  • Muhammad Malik
  • Tao Lu
  • Steven Park
  • Xinying Li
  • David S. Perlin
  • Xilin Zhao
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)


Minimal Inhibitory Concentration Streptococcus Pneumoniae Antimicrob Agent Selection Window Antimicrobial Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aarestrup, F., Seyfarth, A., Emborg, H., Pedersen, K., Hendriksen, R. and Bager, F., (2001), Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob Agents Chemother, 45, 2054–2059.PubMedGoogle Scholar
  2. Acar, J. and Goldstein, F., (1997), Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis, 24, S67-S73.PubMedGoogle Scholar
  3. Almeida, D., Rodrigues, C., Udwadia, Z., Lalvani, A., Gothi, G., Mehta, P. and Mehta, A., (2003), Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis, 36, e152–e154.PubMedGoogle Scholar
  4. Alonso, G., Baptista, K., Ngo, T. and Taylor, D., (2005), Transcriptional organization of the temperature-sensitive transfer system from the IncHI1 plasmid R27. Microbiology, 35, 3563–3573.Google Scholar
  5. Ambrose, P., Zoe-Powers, A., Russo, R., Jones, D. and Owens, R., (2002), Utilizing pharmacodynamics and pharmacoeconomics in clinical and formulary decision making. In C. Nightingale, T. Murakawa, and P. Ambrose, editors, Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York, Marcel Dekker, pp. 385–409.Google Scholar
  6. Andes, D. and Craig, W., (2002), Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother, 46, 1665–1670.PubMedGoogle Scholar
  7. Anonymous (2004) Hospital hygiene sweeps resistance under the carpet. The Lancet Infect Dis, 4, 713.Google Scholar
  8. Balaban, N., Merrin, J., Chait, R., Kowalik, L. and Leibler, S., (2004), Bacterial persistence as a phenotypic switch. Science, 305, 1622–1625.PubMedGoogle Scholar
  9. Bangsberg, D., Charlebois, E., Grant, R., Holodniy, M., Deeks, S., Perry, S., Conroy, K., Clark, R., Guzman, D., Zolopa, A. and Moss, A., (2003), High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 17, 1925–1932.PubMedGoogle Scholar
  10. Bangsberg, D.R., Moss, A.R. and Deeks, S.G., (2004), Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother, 53, 696–699.PubMedGoogle Scholar
  11. Bannon, J., Hatem, M. and Noone, M., (1998), Anaerobic infections of the urinary tract: are they being missed? J Clin Pathol, 51, 709–710.PubMedGoogle Scholar
  12. Baquero, F., (1990), Resistance to quinolones in Gram-negative microorganisms: mechanisms and prevention. Eur Urol, 17 (Suppl 1), 3–12.PubMedGoogle Scholar
  13. Baquero, F., (2001), Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Updat, 4, 93–105.PubMedGoogle Scholar
  14. Baquero, F., Baquero-Artigao, G., Canton, R. and Garcia-Rey, C., (2002), Antibiotic consumption and resistance selection in Streptococcus pneumoniae. J Antimicrob Chemother, 50 (Suppl S2), 27–37.PubMedGoogle Scholar
  15. Baquero, F. and Negri, M., (1997a), Selective compartments for resistant microorganisms in antibiotic gradients. Bioessays, 19, 731–736.Google Scholar
  16. Baquero, F. and Negri, M., (1997b), Strategies to minimize the development of antibiotic resistance. J Chemother, 9 (Suppl), 29–37.Google Scholar
  17. Baquero, F., Negri, M., Morosini, M. and Blazquez, J., (1997), The antibiotic selective process: concentration-specific amplification of low-level resistant populations. Ciba Found Symp, 207, 93–105.PubMedGoogle Scholar
  18. Beaber, J.W., Hochhut, B. and Waldor, M.K., (2004), SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature, 427, 72–74.PubMedGoogle Scholar
  19. Bhavnani, S.M., Hammel, J., Jones, R. and Ambrose, P., (2005), Relationship between increased levofloxacin use and decreased susceptiblity of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis, 51, 31–37.PubMedGoogle Scholar
  20. Binda, G., Domenichini, A., Gottardi, A., Orlandi, B., Ortelli, E., Pacini, B. and Fowst, G., (1971), Rifampicin, a general review. Arzneim Forsch, 21, 1908–1977.Google Scholar
  21. Bingen, E., Lambert-Zechovsky, N., Mariani-Kurkdjian, P., Doit, C., Aujard, Y., Fournerie, F. and Mathieu, H., (1990), Bacterial counts in cerebrospinal fluid of children with meningitis. Eur J Clin Microbiol Infect Dis, 9, 278–281.PubMedGoogle Scholar
  22. Blaser, J., Stone, B., Groner, M. and Zinner, S., (1987), Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother, 31, 1054–1060.PubMedGoogle Scholar
  23. Blondeau, J., Hansen, G., Metzler, K. and Hedlin, P., (2004), The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother, Suppl 3, 1–19.Google Scholar
  24. Blondeau, J., Zhao, X., Hansen, G. and Drlica, K., (2001), Mutant prevention concentrations (MPC) or fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother, 45, 433–438.PubMedGoogle Scholar
  25. Blumberg, (1991), Rapid development of ciprofloxacin resistance in methicillin-susceptible and-resistant Staphylococcus aureus. J Infect Dis, 63, 1279–1285.Google Scholar
  26. Bonhoeffer, S. and Nowak, M., (1997), Pre-existence and emergence of drug resistance in HIV-1 infection. Proc R Soc Lond B Biol Sci, 264, 631–637.Google Scholar
  27. British Medical Research Council, (1950), Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid. Br Med J, 2, 1073–1085.Google Scholar
  28. Burke, J.P., (2003), Infection control—a problem for patient safety. N Engl J Med, 348, 651–656.PubMedGoogle Scholar
  29. Campion, J., Chung, P., McNamara, P., Titlow, W. and Evans, M., (2005a), Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother, 49, 2189–2199.Google Scholar
  30. Campion, J., McNamara, P. and Evans, M., (2005b), Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother, 49, 209–219.Google Scholar
  31. Campion, J., McNamara, P. and Evans, M.E., (2004), Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother, 48, 4733–4744.PubMedGoogle Scholar
  32. Carey, B. and Cryan, B., (2003), Antibiotic misuse in the community—a contributor to resistance? Irish Med J, 96, 43–45.Google Scholar
  33. Chopra, I., O’Neill, A. and Miller, K., (2003), The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat, 6, 137–145.PubMedGoogle Scholar
  34. Chow, J., Fine, M., Shlaes, D., Quinn, J., Hooper, D., Johnson, M., Ramphal, R., Wagener, M., Miyashiro, D. and Yu, V., (1991), Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med, 115, 585–590.PubMedGoogle Scholar
  35. Cirz, R., Chin, J., Andes, D., Crecy-Lagard, V., Craig, W. and Romesberg, F.E., (2005), Inhibition of mutation and combating the evolution of antibiotic resistance. Plos Biol, 3, 1024–1033.Google Scholar
  36. Cizman, M., (2003), The use and resistance to antibiotics in the community. Int J Antimicrob Agents, 21, 297–307.PubMedGoogle Scholar
  37. Coker, R.J., (2004), Multidrug-resistant tuberculosis: public health challenges. Trop Med Int Health, 9, 25–40.PubMedGoogle Scholar
  38. Craig, W., (1998), Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis, 26, 1–12.PubMedGoogle Scholar
  39. Craig, W., (2001), Does the dose matter? Clin Infect Dis, 33, S233–S237.PubMedGoogle Scholar
  40. Craig, W.A., (2002), Pharmacodynamics of antimicrobials: general concepts and applications. In C. Nightingale, T. Murakawa and P. Ambrose, editors, Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York, Marcel Dekker, pp. 1–22.Google Scholar
  41. Croisier, D., Etienne, M., Piroth, L., Bergoin, E., Lequeu, C., Portier, H. and Chavanet, P., (2004), In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of quinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother, 54, 640–647.PubMedGoogle Scholar
  42. Croom, K.F. and Goa, K.L., (2003), Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs, 63, 2769–2802.PubMedGoogle Scholar
  43. Cross, E., Park, S. and Perlin, D.S., (2000), Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb Drug Res, 6, 155–161.Google Scholar
  44. Cui, J., Liu, Y., Wang, R., Tong, W., Drlica, K. and Zhao, X., (2006), The mutant selection window demonstrated in rabbits infected with Staphylococcus aureus. J Infect Dis, 194, 1601–1608.PubMedGoogle Scholar
  45. Dan, M., (2004), The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance. Expert Opin Pharmacother, 5, 829–854.PubMedGoogle Scholar
  46. Davidson, R., Cavalcanti, R., Brunton, J., Bast, D.J., deAzavedo, J.C., Kibsey, P., Fleming, C. and Low, D.E., (2002), Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med, 346, 747–750.PubMedGoogle Scholar
  47. Dean, N., (2003), Encouraging news from the antibiotic resistance front. Chest, 124, 423–424.PubMedGoogle Scholar
  48. Discotto, L.F., Lawrence, L., Denbleyker, K. and Barrett, J.F., (2001), Staphylococcus aureus mutants selected by BMS-284756. Antimicrob Agents Chemother, 45, 3273–3275.PubMedGoogle Scholar
  49. Doern, G.V., Richter, S., Miller, A., Miller, N., Rice, C., Heilmann, K. and Beekmann, S., (2005), Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis, 41, 139–148.PubMedGoogle Scholar
  50. Dong, Y., Xu, C., Zhao, X., Domagala, J. and Drlica, K., (1998), Fluoroquinolone action against mycobacteria: effects of C8 substituents on bacterial growth, survival, and resistance. Antimicrob Agents Chemother, 42, 2978–2984.PubMedGoogle Scholar
  51. Dong, Y., Zhao, X., Domagala, J. and Drlica, K., (1999), Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother, 43, 1756–1758.PubMedGoogle Scholar
  52. Dong, Y., Zhao, X., Kreiswirth, B. and Drlica, K., (2000), Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 44, 2581–2584.PubMedGoogle Scholar
  53. Drlica, K., (2003), The mutant selection window and antimicrobial resistance. J Antimicrob Chemother, 52, 11–17.PubMedGoogle Scholar
  54. Drlica, K. and Zhao, X., (2003), Controlling antibiotic resistance: strategies based on the mutant selection window. In I.W. Fong and K. Drlica, editors, Re-emergence of Established Microbial Pathogens in the 21st Century. New York, Kluwer Academic/Plenum Publishers, pp. 295–331.Google Scholar
  55. Drlica, K., Zhao, X., Blondeau, J. and Hesje, C., (2006), Low correlation between minimal inhibitory concentration (MIC) and mutant prevention concentration (MPC). Antimicrob Agents Chemother, 50, 403–404.PubMedGoogle Scholar
  56. East African Hospitals and British Medical Research Council, (1960), Comparative trial of isoniazid alone in low and high dosage and isoniazid plus PAS in the treatment of acute pulmonary tuberculosis in East Africa. Tubercle, 40, 83–102.Google Scholar
  57. Ehrlich, P., (1913), Chemotherapeutics: scientific principles, methods and results. Lancet, ii, 445–451.Google Scholar
  58. Eliopoulos, G., Gardella, A. and R. Moellering, J., (1984), In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother, 25, 331–335.PubMedGoogle Scholar
  59. Espinal, M.A., (2003), The global situation of MDR-TB. Tuberculosis, 83, 44–51.PubMedGoogle Scholar
  60. Etienne, M., Croisier, D., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Drlica, K. and Chavanet, P., (2004), Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis, 190, 1472–1475.PubMedGoogle Scholar
  61. Fagon, J., Chastre, J., Trouillet, J., Domart, Y., Dombret, M., Bornet, M. and Gibert, C., (1990), Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis, 142, 1004–1008.PubMedGoogle Scholar
  62. Feldman, C., (2004), Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med, 143, 269–283.PubMedGoogle Scholar
  63. Feldman, W., (1976), Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J Pediatr, 88, 549–552.PubMedGoogle Scholar
  64. Felmingham, D., (2002), The need for antimicrobial resistance surveillance. J Antimicrob Chemother, 50 (Suppl S1), 1–7.PubMedGoogle Scholar
  65. Fink, M., Snydman, D., Niederman, M., Leeper, K., Johnson, R., Heard, S., Wunderink, R., Caldwell, J., Schentag, J., Siami, G., Zameck, R., Haverstock, D., Reinhart, H., Echols, R. and Group, S.P.S., (1994), Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem–cilastatin. Antimicrob Agents Chemother, 38, 547–557.PubMedGoogle Scholar
  66. Firsov, A., Smirnova, M., Lubenko, I., Vostrov, S., Portnoy, Y., and Zinner, S., (2006), Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother, 58, 1185–1192PubMedGoogle Scholar
  67. Firsov, A., Vostrov, S., Lubenko, I., Arzamastsev, A., Portnoy, Y. and Zinner, S., (2004a), ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother, 54, 178–186.Google Scholar
  68. Firsov, A., Vostrov, S., Lubenko, I., Drlica, K., Portnoy, Y. and Zinner, S., (2003), In vitro pharmacodynamic evaluation of the mutant selection window hypothesis: four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother, 47, 1604–1613.PubMedGoogle Scholar
  69. Firsov, A., Vostrov, S., Lubenko, I., Zinner, S. and Portnoy, Y., (2004b), Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Int J Antimicrob Agents, 23, 60–66.Google Scholar
  70. Fox, W., Elklard, G. and Mitchison, D., (1999), Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis, 3, S231–S279.PubMedGoogle Scholar
  71. Friedman, S.M., Lu, T. and Drlica, K., (2001), A mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone-resistance-determining region. Antimicrob Agents Chemother, 45, 2378–2380.PubMedGoogle Scholar
  72. Fuller, J.D. and Low, D.E., (2005), A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis, 41, 118–121.PubMedGoogle Scholar
  73. Fung-Tomc, J., Valera, L., Minassian, B., Bonner, D. and Gradelski, E., (2001), Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci. J Antimicrob Chemother, 48, 735–748.PubMedGoogle Scholar
  74. Gajjar, D., Bello, A., Ge, Z., Christopher, L. and Grasela, D., (2003), Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother, 47, 2256–2263.PubMedGoogle Scholar
  75. Gillespie, S.H., Voelker, L.L., Ambler, J., Traini, C. and Dickens, A., (2003), Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb Drug Res, 9, 17–24.Google Scholar
  76. Gonzalez, M., Uribe, F., Moisen, S., Fuster, A., Selen, A., Welling, P. and Painter, B., (1984), Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother, 26, 741–744.PubMedGoogle Scholar
  77. Gudas, L.J. and Pardee, A.B., (1976), DNA synthesis inhibition and the induction of protein X in Eschericia coli. J Mol Biol, 101, 459–477.PubMedGoogle Scholar
  78. Gumbo, T., Louie, A., Deziel, M., Parsons, L., Salfinger, M. and Drusano, G., (2004), Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis, 190, 1642–1651.PubMedGoogle Scholar
  79. Hall, R.M., (1997), Mobile gene cassettes and integrons: moving antibiotic resistance genes in gram-negative bacteria. Ciba Found Symp, 207, 192–202.PubMedGoogle Scholar
  80. Hansen, G., Zhao, X., Drlica, K. and Blondeau, J., (2006), Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents, 27, 120–124.PubMedGoogle Scholar
  81. Hecker, M., Aron, D., Patel, N., Lehmann, M. and Donskey, C., (2003), Unnecessary use of antimicrobials in hospitalized patients. Arch Intern Med, 163, 972–978.PubMedGoogle Scholar
  82. Hermsen, E., Hovde, L., Konstantinides, G. and Rotschafer, J., (2005), Mutant prevention concentration of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Antimicrob Agents Chemother, 49, 1633–1635.PubMedGoogle Scholar
  83. Hovde, L., Rotschafer, S., Ibrahim, K., Gunderson, B., Hermsen, E. and Rotschafer, J., (2003), Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis, 45, 265–267.PubMedGoogle Scholar
  84. Ince, D., Zhang, X., Silver, C., and Hooper, D.C., (2002), Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother, 46, 3370–3380.PubMedGoogle Scholar
  85. Iseman, M., (1994), Evolution of drug-resistant tuberculosis: a tale of two species. Proc Natl Acad Sci USA, 91, 2428–2429.PubMedGoogle Scholar
  86. Jernigan, J., Titus, M., Groschel, D., Getchell-White, S. and Farr, B., (1996), Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol, 143, 496–504.PubMedGoogle Scholar
  87. Jones, R., Pfaller, M., Stilwell, M. and SENTRY-Antimicrobial-Surveillance-Program-Participants-Group, (2001), Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. Diagn Microbiol Inf Dis, 39, 133–135.Google Scholar
  88. Jourdain, B., Novara, A., Joly-Guillou, M., Dombret, M., Calvat, S., Trouillet, J., Gilbert, C. and Chastre, J., (1995), Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med, 152, 241–246.PubMedGoogle Scholar
  89. Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M., Tam, V., Bachhawat, R., Freeman, C., Kahn, J., Bush, K., Dudley, M., Miller, M. and Drusano, G., (2003), Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest, 112, 275–285.PubMedGoogle Scholar
  90. Kawamura, Y., Fujiwara, H., Mishima, N., Tanaka, Y., Tanimoto, A., Ikawa, S., Itoh, Y. and Ezaki, T., (2003), First Streptococcus agalactiae isolates highly resistant to quinolones with point mutations in gyrA and parC. Antimicrob Agents Chemother, 47, 3605–3609.PubMedGoogle Scholar
  91. Kotilainen, P., Routamaa, M., Peltonen, R., Oksi, J., Rintala, E., Meurman, O., Lehtonen, O., Eerola, E., Salmenlinna, S., Vuopio-Varkila, J. and Rossi, T., (2003), Elimination of epidemic methicillin-resistant Staphylococcus aureus from a university hospital and district institutions, Finland. Emerg Infect Dis, 9, 169–175.PubMedGoogle Scholar
  92. Kuga, A., Okamoto, R. and Inoue, M., (2000), ampR gene mutations that greatly increase class C β-lactamase activity in Enterobacter cloacae. Antimicrob Agents Chemother, 44, 561–567.PubMedGoogle Scholar
  93. Kummerer, K. and Henninger, A., (2003), Promoting resistance by the emission of antibiotics from hospitals and households into effluent. Clin Microbiol Infect, 9, 1203–1214.PubMedGoogle Scholar
  94. Lautenbach, E., Strom, B., Nachamkin, I., Bilker, W., Marr, A., Larosa, L. and Fishman, N., (2004), Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989–2000; differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis, 38, 655–662.PubMedGoogle Scholar
  95. Levy, S., (2002), The 2000 Garrod lecture: factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother, 49, 25–30.PubMedGoogle Scholar
  96. Levy, S.B. and Marshall, B., (2004), Antibacterial resistance worldwide: causes, challenges, and responses. Nat Med, 10, S122-S129.PubMedGoogle Scholar
  97. Li, X., Mariano, N., Rahal, J.J., Urban, C.M. and Drlica, K., (2004a), Quinolone-resistant Haemophilus influenzae in a long-term care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob Agents Chemother, 48, 3570–3572.Google Scholar
  98. Li, X., Mariano, N., Rahal, J.J., Urban, C.M. and Drlica, K., (2004b), Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother, 48, 4460–4462.Google Scholar
  99. Li, X., Zhao, X. and Drlica, K., (2002), Selection of Streptococcus pneumoniae mutants having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob Agents Chemother, 46, 522–524.PubMedGoogle Scholar
  100. Lieberman, J., (2003), Appropriate antibiotic use and why it is important: the challenges of bacterial resistance. Pediatr Infect Dis J, 22, 1143–1151.PubMedGoogle Scholar
  101. Linde, H.-J. and Lehn, N., (2004), Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother, 53, 252–257.PubMedGoogle Scholar
  102. Lipsitch, M. and Levin, B., (1997), The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother, 41, 363–373.PubMedGoogle Scholar
  103. Lipsitch, M. and Levin, B., (1998), Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberc Lung Dis, 2, 187–199.PubMedGoogle Scholar
  104. Liu, Y., Cui, J., Wang, R., Wang, X., Drlica, K. and Zhao, X., (2005), Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother, 56, 1172–1175.PubMedGoogle Scholar
  105. Lowy, F.D., (2003), Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest, 111, 1265–1273.PubMedGoogle Scholar
  106. Lu, T., Zhao, X., Li, X., Drlica-Wagner, A., Wang, J.-Y., Domagala, J. and Drlica, K., (2001), Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother, 45, 2703–2709.PubMedGoogle Scholar
  107. Lu, T., Zhao, X., Li, X., Hansen, G., Blondeau, J. and Drlica, K., (2003), Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin, and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother, 52, 61–64.PubMedGoogle Scholar
  108. Luo, H., Wan, K. and Wang, H., (2005), High-frequency conjugation system facilitates biofilm formation and pAMβ1 transmission by Lactococcus lactis. Appl Environ Microbiol, 71, 2970–2978.PubMedGoogle Scholar
  109. Marcusson, L., Olofsson, S., Lindgren, P., Cars, O. and Hughes, D., (2005), Mutant prevention concentration of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother, 55, 938–943.PubMedGoogle Scholar
  110. Markham, P. and Neyfakh, A., (1996), Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother, 40, 2673–2675.PubMedGoogle Scholar
  111. Marr, K., Lyons, C., Ha, K., Rustad, T. and White, T., (2001), Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother, 45, 52–59.PubMedGoogle Scholar
  112. Mathema, B., Cross, E., Dun, E., Park, S., Dedell, J., Slade, B., Williams, M., Riley, L., Chaturvedi, V. and Perliln, D.S., (2001), Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis, 33, e23-e27.PubMedGoogle Scholar
  113. Metzler, K., Hansen, G., Hedlin, P., Harding, E., Drlica, K. and Blondeau, J., (2004), Comparison of minimal inhibitory and mutant prevention concentrations of 4 fluoroquinolones: methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents, 24, 161–167.PubMedGoogle Scholar
  114. Michael, C.A., Gillings, M., Holmes, A., Hughes, L., Andrew, N., Holley, M. and Stokes, H., (2004), Mobile gene cassettes: a fundamental resource for bacterial evolution. Am Nat, 164, 1–12.PubMedGoogle Scholar
  115. Miller, C., Thomsen, L., Gaggero, C., Mosseri, R., Ingmer, H. and Cohen, S., (2004), SOS response induction by β-lactams and bacterial defense against antibiotic lethality. Science, 305, 1629–1631.PubMedGoogle Scholar
  116. Miller, J., (1996), Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu. Rev. Microbiol. 50, 625–643.PubMedGoogle Scholar
  117. Minami, S., Yotsuji, A., Inoue, M. and Mitsuhashi, S., (1980), Induction of β -lactamase by various β-lactam antibiotics in Enterobacter cloacae. Antimicrob Agents Chemother, 18, 382–385.PubMedGoogle Scholar
  118. Mitchison, D.A., (1984), Drug resistance in mycobacteria. Br Med Bull, 40, 84–90.PubMedGoogle Scholar
  119. Mouton, J., Dudley, M., Cars, O., Derendorf, H. and Drusano, G., (2005), Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother, 55, 601–607.PubMedGoogle Scholar
  120. Muller, V. and Bonhoeffer, S., (2003), Mathematical approaches in the study of viral kinetics and drug resistance in HIV-1 infection. Curr Drug Targets Infect Disord, 3, 329–344.PubMedGoogle Scholar
  121. Nazir, J., Urban, C., Mariano, N., Burns, J., Tommasulo, B., Rosenberg, C., Segal-Maurer, S. and Rahal, J., (2004), Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. Clin Infect Dis, 38, 1564–1569.PubMedGoogle Scholar
  122. Negri, M. and Baquero, F., (1998), In vitro selective concentrations of cefapime and ceftazidime AmpC beta-lactamase hyperproduce Enterobacter cloacae variants. Clin Microbiol Infect, 4, 585–588.PubMedGoogle Scholar
  123. Negri, M., Morosini, M., Loza, E. and Baquero, F., (1994), In vitro selective antibiotic concentrations of β-lactams for penicillin-resistant Streptococcus pneumoniae populations. Antimicrob Agents Chemother, 38, 122–125.PubMedGoogle Scholar
  124. Negri, M.-C., Lipsitch, M., Blazquez, J., Levin, B.R. and Baquero, F., (2000), Concentration-dependent selection of small phenotypic differences in TEM β-lactamase-mediated antibiotic resistance. Antimicrob Agents Chemother, 44, 2485–2491.PubMedGoogle Scholar
  125. Oliver, A., Levin, B., Juan, C., Baquero, F. and Blazquez, J., (2004), Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother, 48, 4226–4233.PubMedGoogle Scholar
  126. Olofsson, S., Marcusson, L., Komp-Lindgren, P., Hughes, D. and Cars, O., (2006), Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother, 57, 1116–1121.PubMedGoogle Scholar
  127. Oppegaard, H., Steinum, T. and Wasteson, Y., (2001), Horizontal transfer of a multi-drug resistance plasmid between coliform bacteria of human and bovine origin in a farm environment. Appl Environ Microbiol, 67, 3732–3734.PubMedGoogle Scholar
  128. Pechere, J.-C., (2001), Patients’ interviews and misuse of antibiotics. Clin Infect Dis, 33 (Suppl 3), S170–S173.PubMedGoogle Scholar
  129. Peterson, L.R. and Dalhoff, A., (2004), Toward target prescribing: will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing? J Antimicrob Chemother, 53, 902–905.PubMedGoogle Scholar
  130. Phillips, I., Culebras, E., Moreno, F. and Baquero, F., (1987), Induction of the SOS response by new 4-quinolones. J Antimicrob Chemother, 20, 631–638.PubMedGoogle Scholar
  131. Pittet, D., (2003), Hand hygiene: improved standards and practice for hospital care. Curr Opin Infect Dis, 16, 327–335.PubMedGoogle Scholar
  132. Projan, S. and Shlaes, D., (2004), Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect, 10 (Suppl 4), 18–22.PubMedGoogle Scholar
  133. Randall, L., Cooles, S., Piddock, L. and Woodward, M., (2004), Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica. J Antimicrob Chemother, 54, 688–691.PubMedGoogle Scholar
  134. Regoes, R., Wiuff, C., Zappala, R., Garner, K., Baquero, F. and Levin, B., (2004), Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother, 48, 3670–3676.PubMedGoogle Scholar
  135. Rice, L., Eckstein, E., DeVente, J. and Shlaes, D., (1996), Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis, 23, 118–124.PubMedGoogle Scholar
  136. Rodriguez, J., Cebrian, L., Lopez, M., Ruiz, M., Jimenez, I. and Royo, G., (2004a), Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother, 53, 441–444.Google Scholar
  137. Rodriguez, J., Cebrian, L., Lopez, M., Ruiz, M. and Royo, G., (2004b), Mutant prevention concentration: a new tool for choosing treatment in nontuberculous mycobacterial infections. Int J Antimicrob Agents, 24, 352–356.Google Scholar
  138. Rodriguez, J., Cebrian, L., Lopez, M., Ruiz, M. and Royo, G., (2005), Usefulness of various antibiotics against Mycobacterium avium-intracellulare, measured by their mutant prevention concentration. Int J Antimicrob Agents 25, 221–225.PubMedGoogle Scholar
  139. Sahm, D. and Tenover, F., (1997), Surveillance for the emergence and dissemination of antimicrobial resistance in bacteria. Infect Dis Clin North Am, 11, 767–783.PubMedGoogle Scholar
  140. Seppala, H., Klaukka, T., Vuopio-Varkila, J., Maotiala, A., Helenius, H. and Lager, K., (1997), The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med, 337, 441–446.PubMedGoogle Scholar
  141. Shockley, T. and Hotchkiss, R., (1970), Stepwise introduction of transformable penicillin resistance in pneumococcus. Genetics 64, 397–408.PubMedGoogle Scholar
  142. Shopsin, B., Gomez, M., Montgomery, S., Smith, D.H., Waddington, M., Dodge, D.E., Bost, D., Riehman, M., naidich, S. and Kreiswirth, B.N., (1999), Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol, 37, 3556–3563.PubMedGoogle Scholar
  143. Sieradzki, K., Leski, T., Dick, J., Borio, L., and Tomasz, A., (2003), Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol, 41, 1687–1693.PubMedGoogle Scholar
  144. Sieradzki, K., Roberts, R., Haber, S. and Tomasz, A., (1999), The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med, 340, 517–523.PubMedGoogle Scholar
  145. Silverman, J., Oliver, N., Andrew, T. and Li, T., (2001), Resistance studies with daptomycin. Antimicrob Agents Chemother, 45, 1799–1802.PubMedGoogle Scholar
  146. Sindelar, G., Zhao, X., Liew, A., Dong, Y., Zhou, J., Domagala, J. and Drlica, K., (2000), Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother, 44, 3337–3343.PubMedGoogle Scholar
  147. Smith, B. and Walker, G., (1998), Mutagenesis and more: umuDC and the Escherichia coli SOS response. Genetics, 148, 1599–1610.PubMedGoogle Scholar
  148. Smith, H., Walters, M., Hisanaga, T., Zhanel, G. and Hoban, D., (2004), Mutant prevention concentrations for single-step fluoroquinolone-resistant mtuants of wild-type, efflux-positive, or parC or gyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother, 48, 3954–3958.PubMedGoogle Scholar
  149. Strahilevitz, J. and Hooper, D.C., (2005), Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother, 49, 1949–1956.PubMedGoogle Scholar
  150. Stratton, C., (2003), Dead bugs don’t mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis, 9, 10–16.PubMedGoogle Scholar
  151. Tam, V., Louie, A., Deziel, M., Liu, W., Leary, R. and Drusano, G., (2005), Bacterial-population responses to drug-selective pressure: examination of garenoxacin’s effect on Pseudomonas aeruginosa. J Infect Dis, 192, 420–428.PubMedGoogle Scholar
  152. Tillotson, G., Zhao, X. and Drlica, K., (2001), Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes. The Lancet Infect Dis, 1, 145–146.Google Scholar
  153. Wehbeh, W., Rojas-Diaz, R., Li, X., Mariano, N., Grenner, L., Segal-Maurer, S., Tommasulo, B., Drlica, K., Urban, C. and Rahal, J., (2005), Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother, 49, 2495–2497.PubMedGoogle Scholar
  154. Weller, T., Andrews, J., Jevons, G. and Wise, R., (2002), The in vitro activity of BMS-2847676, a new des-fluorinated quinolone. J Antimicrob Chemother, 49, 177–184.PubMedGoogle Scholar
  155. Wetzstein, H.-G., (2005), Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob Agents Chemother, 49, 4166–4173.PubMedGoogle Scholar
  156. Wimberley, N., Faling, L. and Bartlett, J., (1979), A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am Rev Respir Dis, 119, 337–343.PubMedGoogle Scholar
  157. Wiuff, C., Lykkesfeldt, J., Svendsen, O. and Aarestrup, F., (2003), The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs. Res Vet Sci, 75, 185–193.PubMedGoogle Scholar
  158. Yoshida, H., Bogaki, M., Nakamura, M. and Nakamura, S., (1990), Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother, 34, 1271–1272.PubMedGoogle Scholar
  159. Zhanel, G.G., Walters, M., Laing, N. and Hoban, D.J., (2001), In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother, 47, 435–440.PubMedGoogle Scholar
  160. Zhao, X. and Drlica, K., (2001), Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis, 33 (Suppl 3), S147–S156.PubMedGoogle Scholar
  161. Zhao, X. and Drlica, K., (2002), Restricting the selection of antibiotic-resistant mutants: measurement and potential uses of the mutant selection window. J Infect Dis, 185, 561–565.PubMedGoogle Scholar
  162. Zhao, X., Eisner, W., Perl-Rosenthal, N., Kreiswirth, B. and Drlica, K., (2003), Mutant prevention concentration for garenoxacin (BMS-284756) with ciprofloxacin-susceptible and ciprofloxacin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 47, 1023–1027.PubMedGoogle Scholar
  163. Zhao, X., Wang, J.-Y., Xu, C., Dong, Y., Zhou, J., Domagala, J. and Drlica, K., (1998), Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother, 42, 956–958.PubMedGoogle Scholar
  164. Zhao, X., Xu, C., Domagala, J. and Drlica, K., (1997), DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA, 94, 13991–13996.PubMedGoogle Scholar
  165. Zhou, J.-F., Dong, Y., Zhao, X., Lee, S., Amin, A., Ramaswamy, S., Domagala, J., Musser, J.M. and Drlica, K., (2000), Selection of antibiotic resistance: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis, 182, 517–525.PubMedGoogle Scholar
  166. Zinner, S., Lubenko, I., Gilbert, D., Simmons, K., Zhao, X., Drlica, K. and Firsov, A., (2003), Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentration in and out of the mutant selection window: related changes in susceptibility, resistance frequency, and bacterial killing. J Antimicrob Chemother, 52, 616–622.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Karl Drlica
  • J.-Y. Wang
  • Muhammad Malik
  • Tao Lu
  • Steven Park
  • Xinying Li
  • David S. Perlin
  • Xilin Zhao

There are no affiliations available

Personalised recommendations